Trial Profile
A multicenter double-blind randomized placebo-controlled phase IIB test-of-concept study to evaluate the safety and efficacy of a three-dose regimen of the Clade B-based Merck adenovirus serotype 5 HIV-1 Gag/Pol/Nef vaccine in HIV-1 uninfected adults in South Africa.
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2022
Price :
$35
*
At a glance
- Drugs V 520 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Acronyms Phambili
- 15 Oct 2016 Results published in the Vaccine
- 01 Aug 2016 Status changed from completed to suspended, according to results published in the Journal of Infectious Diseases.
- 15 Apr 2014 Status changed from suspended to completed, as per ClinicalTrials.gov record.